Unresectable Rectal Adenocarcinoma
我们是谁
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
SX-682和Nivolumab治疗RAS突变、MSS不可切除或转移性结直肠癌的STOPTRAFFIC-1试验